MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE.
Fox RJ, et al.
Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28.
Neurology. 2014.
PMID: 24682966
Free PMC article.
Clinical Trial.